NASDAQ:ARTL Artelo Biosciences Q2 2025 Earnings Results & Report $1.35 -0.10 (-6.97%) Closing price 11/20/2026 03:58 PM EasternExtended Trading$1.37 +0.02 (+1.26%) As of 11/20/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Artelo Biosciences missed analyst earnings expectations in its Q2 2025 results, released August 13, 2025. The company reported EPS of -$151.47 versus the -$3.51 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 13, 2025TimeBefore Market OpensConference Call7:00 AM ET Artelo Biosciences EPS ResultsActual EPS-$151.47Consensus EPS -$3.51Beat/MissMissed by -$147.96One Year Ago EPSN/AEPS Beat Rate3 of last 4 quartersArtelo Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Artelo Biosciences Q2 2025 Earnings FAQ Did Artelo Biosciences beat earnings estimates for Q2 2025? Artelo Biosciences (NASDAQ:ARTL) reported earnings of -$151.47 per share for Q2 2025, missing the consensus estimate of -$3.51. The report was announced on Wednesday, August 13, 2025. Artelo Biosciences Earnings HeadlinesArtelo Biosciences Provides Business Update and Reports 2026 Third Quarter Financial ResultsNovember 12, 2026 | markets.businessinsider.comArtelo Biosciences consensus price target increased 2,600% to $826.20November 2, 2026 | msn.comCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.November 22 at 1:00 AM | Decentralized Masters (Ad)Artelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on PainOctober 29, 2026 | globenewswire.comArtelo Biosciences to Present ART26.12 Data at IASP World Congress on Pain as First Selective FABP5 Inhibitor Advances Toward MAD StudyOctober 26, 2026 | quiverquant.comQArtelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on PainOctober 26, 2026 | globenewswire.comSee More Artelo Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Artelo Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Artelo Biosciences and other key companies, straight to your email. Email Address About Artelo BiosciencesArtelo Biosciences (NASDAQ:ARTL) is a clinical-stage biopharmaceutical company developing treatments that target the endocannabinoid system and related biological pathways. Its research focuses on potential therapies for conditions with significant unmet medical needs, including cancer-related symptoms and pain. The company’s programs have included ART27.13, a cannabinoid receptor agonist being studied for cancer-related anorexia and cachexia, and ART26.12, a small-molecule inhibitor of fatty acid binding protein 5 under investigation for potential therapeutic applications. Artelo has also developed ART12.11, a cannabidiol-based cocrystal formulation. Artelo is headquartered in the San Diego area of California. Its work is centered on drug research and development rather than the commercial sale of approved medicines.View Artelo Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/16 - 11/20If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in LimboAirfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter TestOwens Corning's Stock Slump May Have a Silver Lining for Dividend InvestorsThe Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity StocksHard Drives Were Left for Dead, But Seagate and Western Digital Are Soaring Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.